

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION PURSUANT TO ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

8 April 2025

**Belluscura plc**  
**("Belluscura" or the "Company")**

**Statement re proposed imposition of Tariffs**

Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, notes the proposed imposition of tariffs on imports to the United States of America announced by the US Administration last week.

The Company is currently assessing the potential financial implications, risks and opportunities of the imposition of tariffs, in particular the 54% tariff (previously 20%) for goods imported from China, in which a significant proportion of the Company's Portable Oxygen Concentrators, raw materials and component parts are currently manufactured.

In the light of the above, the Company withdraws its previous market guidance for the current year ending 31 December 2025 (as referred to in its notification of 6 February 2025).

The Company expects to make a further announcement once it has been able to better assess the situation, including possible subsequent developments.

**For further information please contact:**

**Belluscura plc**  
Paul Tuson, Chairman  
Robert Rauker, Chief Executive Officer  
Simon Neicheril, Chief Financial Officer

Tel: +44 (0)20 3128 8100

**SPARK Advisory Partners Limited**  
**Nominated Adviser**  
Neil Baldwin / Jade Bayat

Tel: +44 (0)20 3368 3550

**Dowgate Capital Limited**  
**Joint Broker**  
James Serjeant / Colin Clime (Sales and Corporate Broking)  
Russell Cook / Daniel Ingram (Corporate Finance)

Tel: +44 (0)20 3903 7715

**Allenby Capital Ltd**  
**Joint Broker**  
Guy McDougall / Amrit Nahal (Sales and Corporate Broking)  
Jeremy Porter / Lauren Wright (Corporate Finance)

Tel: +44 (0)20 3328 5656

**MHP**  
**Financial PR & Investor Relations**  
Katie Hunt/Matthew Taylor

Tel: +44 (0)20 3128 8100  
email: [belluscura@mhpgroup.com](mailto:belluscura@mhpgroup.com)

For further information, please visit <https://ir.belluscura.com/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

